中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2013年
5期
503-504
,共2页
血脂%辅酶A%疗效
血脂%輔酶A%療效
혈지%보매A%료효
Blood fat%Coenzyme A%Efficacy
目的:本研究旨在评估天然降脂化合物辅酶A(CoA)胶囊在中度血脂异常患者中的降脂作用和临床安全性。方法纳入2010年9月~2012年12月吴川市人民医院内科门诊的中度血脂异常患者168例,随机分成3组,A组予安慰剂(n=54)、B组予CoA 200U/d(n=46)、C组予CoA 400U/d(n=68)。治疗前和治疗后第4周或第8周后分别检测所有患者血脂、肝肾功能、血糖指标,并记录治疗过程中肌病和胃肠道症状等不良反应。结果与治疗前相比,三组治疗后TG均下降,C组下降最明显[基线 vs.治疗4周vs.治疗8周后:(3.76±0.67)mmol/L vs.(3.22±0.62)mmol/L vs.(2.40±0.54)mmol/L],其次是B组[(3.24±0.95)mmol/L vs.(2.73±0.67)mmol/L vs.(2.54±0.76)mmol/L],A组在第4周下降,第8周反而上升,[(3.57±0.78)mmol/L vs.(3.38±0.57)mmol/L vs.(3.54±0.65)mmol/L];三组血浆总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)治疗前后并无统计学差异(P>0.05)。同时,三组血糖、肝肾功能,肌病或胃肠道症状发病率无显著差异(P均>0.05)。结论CoA能有效降低中度血脂异常患者的血浆TG水平,未发现明显的副作用。
目的:本研究旨在評估天然降脂化閤物輔酶A(CoA)膠囊在中度血脂異常患者中的降脂作用和臨床安全性。方法納入2010年9月~2012年12月吳川市人民醫院內科門診的中度血脂異常患者168例,隨機分成3組,A組予安慰劑(n=54)、B組予CoA 200U/d(n=46)、C組予CoA 400U/d(n=68)。治療前和治療後第4週或第8週後分彆檢測所有患者血脂、肝腎功能、血糖指標,併記錄治療過程中肌病和胃腸道癥狀等不良反應。結果與治療前相比,三組治療後TG均下降,C組下降最明顯[基線 vs.治療4週vs.治療8週後:(3.76±0.67)mmol/L vs.(3.22±0.62)mmol/L vs.(2.40±0.54)mmol/L],其次是B組[(3.24±0.95)mmol/L vs.(2.73±0.67)mmol/L vs.(2.54±0.76)mmol/L],A組在第4週下降,第8週反而上升,[(3.57±0.78)mmol/L vs.(3.38±0.57)mmol/L vs.(3.54±0.65)mmol/L];三組血漿總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)和高密度脂蛋白膽固醇(HDL-C)治療前後併無統計學差異(P>0.05)。同時,三組血糖、肝腎功能,肌病或胃腸道癥狀髮病率無顯著差異(P均>0.05)。結論CoA能有效降低中度血脂異常患者的血漿TG水平,未髮現明顯的副作用。
목적:본연구지재평고천연강지화합물보매A(CoA)효낭재중도혈지이상환자중적강지작용화림상안전성。방법납입2010년9월~2012년12월오천시인민의원내과문진적중도혈지이상환자168례,수궤분성3조,A조여안위제(n=54)、B조여CoA 200U/d(n=46)、C조여CoA 400U/d(n=68)。치료전화치료후제4주혹제8주후분별검측소유환자혈지、간신공능、혈당지표,병기록치료과정중기병화위장도증상등불량반응。결과여치료전상비,삼조치료후TG균하강,C조하강최명현[기선 vs.치료4주vs.치료8주후:(3.76±0.67)mmol/L vs.(3.22±0.62)mmol/L vs.(2.40±0.54)mmol/L],기차시B조[(3.24±0.95)mmol/L vs.(2.73±0.67)mmol/L vs.(2.54±0.76)mmol/L],A조재제4주하강,제8주반이상승,[(3.57±0.78)mmol/L vs.(3.38±0.57)mmol/L vs.(3.54±0.65)mmol/L];삼조혈장총담고순(TC)、저밀도지단백담고순(LDL-C)화고밀도지단백담고순(HDL-C)치료전후병무통계학차이(P>0.05)。동시,삼조혈당、간신공능,기병혹위장도증상발병솔무현저차이(P균>0.05)。결론CoA능유효강저중도혈지이상환자적혈장TG수평,미발현명현적부작용。
Objective To review the lipid-lowering effect and safety of coenzyme A (CoA) on serum lipid level in the patients with moderate hyperlipidemia. Methods The patients (n=168) were chosen from the Outpatient Department of Internal Medicine of People’s Hospital of Wuchuan City from Sept. 2010 to Dec. 2012 and randomly divided into three groups. Group A (n=54) was given placebo, group B (n=46) was given CoA (200 U/d) and group C (n=68) was given CoA (400 U/d). The changes of blood fat, functions of liver and kidney and blood glucose indexes were detected, and myopathy and gastrointestinal symptoms were recorded respectively before and 4 weeks and 8 weeks after treatment. Results After treatment, TG level decreased in three groups especially in group C [(3.76±0.67) mmol/L vs. (3.22±0.62) mmol/L vs. (2.40±0.54) mmol/L] followed by group B [(3.24±0.95) mmol/L vs. (2.73±0.67) mmol/L vs. (2.54±0.76) mmol/L]. TG level decreased in group A on the 4th week but increased on the 8th week [(3.57±0.78) mmol/L vs. (3.38±0.57) mmol/L vs. (3.54±0.65) mmol/L]. The levels of TC, LDL-C and HDL-C (P>0.05), and blood glucose indexes, functions of liver and kidney, myopathy and gastrointestinal symptoms had no statistical difference (all P>0.05) in three group before and after treatment. Conclusion CoA can effectively reduce TC level in the patients with moderate hyperlipidemia and has no obvious side effects.